Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
about
JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis.Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8-9 February 2018.MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.
P2860
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Utility of Genomic Analysis In ...... Carcinoma of Unknown Primary.
@en
Utility of Genomic Analysis In ...... Carcinoma of Unknown Primary.
@nl
type
label
Utility of Genomic Analysis In ...... Carcinoma of Unknown Primary.
@en
Utility of Genomic Analysis In ...... Carcinoma of Unknown Primary.
@nl
prefLabel
Utility of Genomic Analysis In ...... Carcinoma of Unknown Primary.
@en
Utility of Genomic Analysis In ...... Carcinoma of Unknown Primary.
@nl
P2093
P2860
P1433
P1476
Utility of Genomic Analysis In ...... Carcinoma of Unknown Primary.
@en
P2093
Brian Leyland-Jones
Casey Williams
Kimberly C Banks
Kirstin Williams
Nithya Krishnamurthy
Richard B Lanman
Scott M Lippman
Shumei Kato
P2860
P304
P356
10.1158/0008-5472.CAN-17-0628
P407
P577
2017-06-22T00:00:00Z